BRPI0813218A2 - Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. - Google Patents
Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.Info
- Publication number
- BRPI0813218A2 BRPI0813218A2 BRPI0813218-6A2A BRPI0813218A BRPI0813218A2 BR PI0813218 A2 BRPI0813218 A2 BR PI0813218A2 BR PI0813218 A BRPI0813218 A BR PI0813218A BR PI0813218 A2 BRPI0813218 A2 BR PI0813218A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- contain
- pharmaceutical composition
- active principle
- aza
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007052598 | 2007-07-03 | ||
| PCT/IB2008/052656 WO2009004584A1 (en) | 2007-07-03 | 2008-07-02 | 3-aza-bicyclo[3.3.0]octane compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813218A2 true BRPI0813218A2 (pt) | 2014-12-23 |
Family
ID=39863067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813218-6A2A BRPI0813218A2 (pt) | 2007-07-03 | 2008-07-02 | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8106215B2 (pt) |
| EP (1) | EP2164847B1 (pt) |
| JP (1) | JP2010531871A (pt) |
| KR (1) | KR20100041805A (pt) |
| CN (1) | CN101730696B (pt) |
| AT (1) | ATE524466T1 (pt) |
| AU (1) | AU2008272449A1 (pt) |
| BR (1) | BRPI0813218A2 (pt) |
| CA (1) | CA2691373A1 (pt) |
| ES (1) | ES2371514T3 (pt) |
| PL (1) | PL2164847T3 (pt) |
| WO (1) | WO2009004584A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010504957A (ja) * | 2006-09-29 | 2010-02-18 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体 |
| JP2010511038A (ja) | 2006-12-01 | 2010-04-08 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体阻害剤としての３−ヘテロアリール（アミノ又はアミド）−１−（ビフェニル又はフェニルチアゾリル）カルボニルピペリジン誘導体 |
| TW200833328A (en) | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| CL2008000836A1 (es) * | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
| WO2009040730A2 (en) * | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| AU2009215243A1 (en) * | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
| EP2318367B1 (en) * | 2008-04-30 | 2013-03-20 | Actelion Pharmaceuticals Ltd. | Piperidine and pyrrolidine compounds |
| MX2011003191A (es) * | 2008-10-14 | 2011-04-27 | Actelion Pharmaceuticals Ltd | Derivados de fenetilamida y sus analogos heterociclicos. |
| DK2491038T3 (da) | 2009-10-23 | 2016-07-18 | Janssen Pharmaceutica Nv | Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer |
| SG11201404738QA (en) | 2012-02-07 | 2014-10-30 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| NZ703448A (en) | 2012-06-04 | 2017-07-28 | Actelion Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
| CN104703980B (zh) | 2012-10-10 | 2017-09-22 | 埃科特莱茵药品有限公司 | 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂 |
| EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
| ITMI20130706A1 (it) * | 2013-04-30 | 2014-10-31 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
| CA2929423C (en) | 2013-12-03 | 2021-12-07 | Actelion Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1 ,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| AU2014358766B2 (en) | 2013-12-04 | 2019-01-17 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
| EP3180332B1 (en) | 2014-08-13 | 2021-10-27 | Eolas Therapeutics Inc. | Difluoropyrrolidines as orexin receptor modulators |
| CN109219606B (zh) | 2016-02-12 | 2021-10-01 | 阿斯利康(瑞典)有限公司 | 食欲素受体调节剂的卤素取代的哌啶 |
| CA3016706A1 (en) | 2016-03-10 | 2017-09-14 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| KR102611212B1 (ko) | 2016-04-19 | 2023-12-07 | 삼성디스플레이 주식회사 | 액정 조성물 및 이를 포함하는 액정 표시 장치 |
| IL276813B2 (en) | 2018-03-05 | 2024-09-01 | Arcus Biosciences Inc | History of 4-substituted 5-amino-octahydrocyclopenta[c]pyrrole-5-carboxylic acid, their pharmaceutical combinations and their use for the treatment of diseases |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| AR129309A1 (es) | 2022-05-13 | 2024-08-07 | Idorsia Pharmaceuticals Ltd | Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57139032A (en) | 1981-02-20 | 1982-08-27 | Takasago Corp | 2-(butan-2-on-3-yl)-5-methylphenol and perfumery composition containing the same |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| US6191124B1 (en) | 1994-04-29 | 2001-02-20 | Pharmacia & Upjohn Company | Methanol derivatives for treatment of retroviral infections especially HIV infections |
| PT1289955E (pt) * | 2000-06-16 | 2005-08-31 | Smithkline Beecham Plc | Piperidinas para utilizacao como antagonistas dos receptores da orexina |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| EP1353918B1 (en) * | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| US7432270B2 (en) | 2001-05-05 | 2008-10-07 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
| GB0127145D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| EP1539747B1 (en) * | 2002-09-18 | 2006-11-02 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| KR101129933B1 (ko) | 2002-09-25 | 2012-03-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도 |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| US7056817B2 (en) * | 2002-11-20 | 2006-06-06 | Intel Corporation | Forming a cap above a metal layer |
| US20050234095A1 (en) | 2004-03-25 | 2005-10-20 | Wenge Xie | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| ES2360376T3 (es) * | 2006-08-15 | 2011-06-03 | Actelion Pharmaceuticals Ltd. | Compuestos de azetidina como antagonistas del receptor de orexina. |
| JP2010504957A (ja) * | 2006-09-29 | 2010-02-18 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体 |
| JP2010511038A (ja) * | 2006-12-01 | 2010-04-08 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体阻害剤としての３−ヘテロアリール（アミノ又はアミド）−１−（ビフェニル又はフェニルチアゾリル）カルボニルピペリジン誘導体 |
| JP2010534647A (ja) * | 2007-07-27 | 2010-11-11 | アクテリオン ファーマシューティカルズ リミテッド | ２−アザ−ビシクロ［３．３．０］オクタン誘導体 |
-
2008
- 2008-07-02 CA CA002691373A patent/CA2691373A1/en not_active Abandoned
- 2008-07-02 ES ES08763445T patent/ES2371514T3/es active Active
- 2008-07-02 EP EP08763445A patent/EP2164847B1/en not_active Not-in-force
- 2008-07-02 KR KR1020107002315A patent/KR20100041805A/ko not_active Application Discontinuation
- 2008-07-02 JP JP2010514232A patent/JP2010531871A/ja not_active Ceased
- 2008-07-02 PL PL08763445T patent/PL2164847T3/pl unknown
- 2008-07-02 BR BRPI0813218-6A2A patent/BRPI0813218A2/pt not_active IP Right Cessation
- 2008-07-02 US US12/667,193 patent/US8106215B2/en not_active Expired - Fee Related
- 2008-07-02 AU AU2008272449A patent/AU2008272449A1/en not_active Abandoned
- 2008-07-02 AT AT08763445T patent/ATE524466T1/de active
- 2008-07-02 WO PCT/IB2008/052656 patent/WO2009004584A1/en active Application Filing
- 2008-07-02 CN CN2008800232482A patent/CN101730696B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL2164847T3 (pl) | 2012-02-29 |
| US20100184808A1 (en) | 2010-07-22 |
| RU2010103322A (ru) | 2011-08-10 |
| JP2010531871A (ja) | 2010-09-30 |
| ATE524466T1 (de) | 2011-09-15 |
| AU2008272449A1 (en) | 2009-01-08 |
| WO2009004584A1 (en) | 2009-01-08 |
| CN101730696A (zh) | 2010-06-09 |
| US8106215B2 (en) | 2012-01-31 |
| EP2164847A1 (en) | 2010-03-24 |
| ES2371514T3 (es) | 2012-01-04 |
| CA2691373A1 (en) | 2009-01-08 |
| EP2164847B1 (en) | 2011-09-14 |
| KR20100041805A (ko) | 2010-04-22 |
| CN101730696B (zh) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813218A2 (pt) | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| BRPI0605921B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
| DOP2009000293A (es) | Derivados de piperidina utiles como antagonistas receptores de orexina. | |
| ATE496051T1 (de) | Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten | |
| MX2009009690A (es) | Derivados de tiazolidina como antagonistas del receptor de orexina. | |
| ATE493386T1 (de) | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate | |
| MX2010001575A (es) | Derivados de 1,2-diamido-etileno como antagonistas de orexina. | |
| ATE500250T1 (de) | Azetidinverbindungen als orexin-rezeptor- antagonisten | |
| BRPI0910182B8 (pt) | composto de fórmula (i), composição farmacêutica e uso de um composto | |
| DOP2011000176A (es) | Compuestos organicos | |
| HN2008001530A (es) | Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| DE602005014086D1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| HN2010001059A (es) | Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes. | |
| ECSP088265A (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| ATE458740T1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten | |
| BRPI0821004A8 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
| UY29440A1 (es) | Nuevos compuestos | |
| CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
| CL2011000784A1 (es) | Compuestos derivados de 7-h-pirazoli[3,4-e]-diasepina-6(5h)-ona sustituidos; procedimiento de preparacion; composicion farmaceutica, utiles como agentes antibacteriales. | |
| BRPI0511999A (pt) | compostos como antagonistas de ccr5 | |
| UY30534A1 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii | |
| BRPI0620985B1 (pt) | composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina | |
| NI201100015A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico. | |
| DE602007005387D1 (de) | Ptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |